ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Hypothermic Oxygenated Machine Perfusion in Liver and Kidney Transplantation of Extended Criteria Donors: A Phase-1 of Clinical Trial

M. Ravaioli,1 V. De Pace,1 M. Cescon,1 M. Del Gaudio,1 V. R. Bertuzzo,1 A. Siniscalchi,1 A. D'Errico,2 G. Comai,2 G. La Manna,2 A. D. Pinna.1

1General Surgery and Transplantation, University of Bologna Sant'Orsola - Malpighi Hospital, Bologna, Emilia Romagna, Italy
2Experimental Diagnostic and Specialty Medicine, University of Bologna Sant'Orsola- Malpighi Hospital, Bologna, Emilia Romagna, Italy.

Meeting: 2018 American Transplant Congress

Abstract number: D281

Keywords: Donors, Graft function, Kidney/liver transplantation, marginal, Preservation

Session Information

Session Name: Poster Session D: Late Breaking

Session Type: Poster Session

Date: Tuesday, June 5, 2018

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall 4EF

In the field of liver (LT) and kidney transplantation (KT), extended criteria donors (ECD) offer an additional organ source that is more vulnerable for early allograft dysfunction (EAD) in LT and delayed graft function (DGF) in KT. We experienced a phase-1 clinical trial (ID: NCT03031067) of ex-vivo hypothermic oxygenated perfusion (HOPE) in LT or KT from ECD brain death donor (DBD).

A matched-case analysis was developed: 10 HOPE-ECD livers and kidneys, HOPE-L and -K groups, were matched 1:3 with livers and kidneys preserved with static cold storage (SCS), SCS-L and -K groups respectively. HOPE-L and SCS-L groups were matched for donor and recipient age, cold ischemia time (CIT), MELD score, portal thrombosis, previous abdominal-surgery and hepatic-steatosis. HOPE-K and SCS K-groups were matched for donor and recipient age, CIT, Karpinsky's score, induction immunosuppressive therapy, peritoneal or hemodialysis and dialyses time.

Following organs retrieval and its transfer at hospital, the grafts were connected to machine perfusion through the renal artery or hepatic portal vein cannulation during surgical back table until the implantation.

Data were reported as mean and SD or median and ranges. Mann-Whitney U test was applied for continuous data and unpaired T test for categorical data with SPSS software; p values less than 0.05 were considered statistically significant.

Organs were perfused for 1-3 hours at median hepatic flow of 100 (116-30) ml/min and median renal flow of 46 (24-85) ml/min. In LT, EAD was 0% for HOPE-L vs 26.6% in SCS-L and in KT (p=0.003), DGF was 20% for HOPE-K vs 36.6% for SCS-K (p=0.313). Primary non-function was 0% for both K-groups and 3.3% for SCS-L vs 0% for HOPE-L. Median peak aspartate aminotransferase within 7-days post-LT was significantly higher in SCS-L, 637 (124-2001) U/L, respect to HOPE-L, 344 (166-1032) U/L, p=0.007. Grafts survival at 30-days post-transplant was 93.4% for SCS-L vs 100% of HOPE-L and 96.7% for SCS-K vs 100% of HOPE-K.

Clinical outcomes support HOPE for ECD-DBD grafts as safe and efficacy to reduce the ischemic preservation injuries in KT, but in LT particularly.

CITATION INFORMATION: Ravaioli M., De Pace V., Cescon M., Del Gaudio M., Bertuzzo V. R., Siniscalchi A., D'Errico A., Comai G., La Manna G., Pinna A. D. Hypothermic Oxygenated Machine Perfusion in Liver and Kidney Transplantation of Extended Criteria Donors: A Phase-1 of Clinical Trial Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Ravaioli M, Pace VDe, Cescon M, Gaudio MDel, Bertuzzo VR, Siniscalchi A, D'Errico A, Comai G, Manna GLa, Pinna AD. Hypothermic Oxygenated Machine Perfusion in Liver and Kidney Transplantation of Extended Criteria Donors: A Phase-1 of Clinical Trial [abstract]. https://atcmeetingabstracts.com/abstract/hypothermic-oxygenated-machine-perfusion-in-liver-and-kidney-transplantation-of-extended-criteria-donors-a-phase-1-of-clinical-trial/. Accessed June 5, 2025.

« Back to 2018 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences